Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Sakigake: Now and Future (3) - Astellas’s FLT3 Inhibitor for AML Receives Designation, but Other Companies Trailing
ASP2215 (gilteritinib), a selective FLT3/AXL inhibitor Astellas Pharma is developing as a treatment for relapsed or treatment-resistant acute myeloid leukemia (AML), obtained designation under the sakigake fast-track review pathway. It was selected because of its novel mechanism of action and…
To read the full story
Related Article
- Sakigake: Now and Future (5) - BioCryst’s BCX7353 Would Be Japan’s 1st Drug for Preventing Angioedema Attacks
April 4, 2016
- Sakigake: Now and Future (4) - MSD’s Anti-PD-1 Antibody Gets Sakigake Designation for Gastric Cancer, While Opdivo also Under Development for Same Indication
March 2, 2016
- Sakigake: Now and Future (2) - Shionogi Aims to Submit Application for Novel Flu Drug as Early as FY2017
February 12, 2016
- Sakigake: Now and Future (1) - Topical Sirolimus on Track for Application in 2018 for 1st-in-World Indication
February 4, 2016
BUSINESS
- Otsuka/Ionis’ HAE Drug Dawnzera Approved in Europe
January 22, 2026
- Shionogi to Lift Stake in ViiV to 21.7% as Pfizer Exits
January 21, 2026
- Fuji Pharma Earns Approval for High-Dose Stelara Biosimilar
January 21, 2026
- Kaken’s Hyperhidrosis Drug Ecclock Now Available in South Korea
January 20, 2026
- Daridorexant Hits Primary Goal in South Korea PIII Insomnia Trial, Nxera Plans Filing in Q1 2026
January 20, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…